• Users Online: 43
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
ARTICLE
Year : 2013  |  Volume : 2  |  Issue : 1  |  Page : 7-13

Assessment of GM-CSF Level in the Serum of Patients with Different Stages of Chronic Myeloid Leukemia Befor and After Imatinb Mesylate Therapy


1 National Center of Hematology, Almustansiriya University
2 Department of Microbiology, College of Medicine, Al-Mustansiriya University
3 Clinical Hematologist, Baghdad Teaching Hospital/ Medical city

Correspondence Address:
Login to access the Email id

Source of Support: None, Conflict of Interest: None


Rights and PermissionsRights and Permissions

Background: Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder of primitive haemopoietic progenitor cells. The cytogenetic hallmark of CML is the Philadelphia chromosome, created by a reciprocal translocation between chromosomes 9&22 (t [9;22][q34;q11]). Survival and amplification of hematopoietic progenitors are controlled by a number of regulatory molecules (hematopoietic growth factors). The role of Granulocyte- macrophage colony-stimulating factor (GM-CSF) and its receptor in pathology arises largely as a result of abnormal signaling leading to deregulated myelopoiesis. The development of the BCR-ABL-targeted Imatinib mesylate represents a paradigm shift in the treatment of CML. Data indicate that the level of immune responses against CML is low before Imatinib, rises as treatment is administered and declines again when the BCR-ABL transcript numbers fall to low levels. Objective: To assess and evaluate the significance of levels difference in GM-CSF through newly diagnosed patients, different responder groups (optimal, suboptimal and failure cytogenetic response) and advanced stages (acceleration and crisis groups) of CML Iraqi patients whom receiving Imatinib mesylate (TKI), as an indicator to assess the role of growth factor in pathogenesis of CML disease development and response to treatments. Patients and methods: In this study 128 Iraqi CML patients asses before and after receiving imatinib mesylate treatment which categorized by complete blood picture and fluorescent in situ hybridization (FISH) analysis in to different response groups and stages, then used an ELISA technique to assess serum level of GM-CSF in each response group and advance stage (acceleration and transformed) of CML patients, in comparison to level in 32 healthy control subjects. Results : Out of 128 patients the mean of GM-CSF serum level (pg/ml) for the newly diagnosed, optimal responded, suboptimal responded, failure cytogenetic and advance stage of CML were 399.53±104.50, 325.23±66.37, 428.90±45.70, 347.12±54.45, 521.56±83.73, respectively. While healthy was 269.25±86.27. Conclusion: Uncontrolled granulopoiesis in newly diagnosed patients with CML may be mediated by increased plasma CSF concentrations caused by BCR-ABL activity which may give an idea regarding the role of colony stimulating factors in the pathogenesis of CML disease.


[PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1138    
    Printed63    
    Emailed0    
    PDF Downloaded94    
    Comments [Add]    

Recommend this journal